Andere Sprachen Aligos Therapeutics, Inc.

Aktien

A2QCEK

US01626L1052

ALGS

Verzögert Nasdaq Andere Börsenplätze 16:40:28 01.05.2024			% 5 Tage	% 1. Jan.
0,7798 ^USD	+1,93 %		-5,93 %	+17,44 %

03.04.	Aligos Therapeutics, Inc. gibt bekannt, dass die ersten Probanden in der Phase-2a-HERALD-Studie mit ALG-055009 bei MASH-Patienten behandelt wurden	CI
27.03.	Aligos Therapeutics präsentiert auf der APASL 2024 positive klinische Daten aus den Phase-1-Studien ALG-055009 und ALG-000184	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30.04.
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30.04.
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25.04.
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25.04.
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25.04.
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25.04.
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	09.04.
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03.04.
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03.04.
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03.04.
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27.03.
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27.03.
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18.03.
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18.03.
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	18.03.
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	12.03.
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	05.03.
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aligos Therapeutics, Inc.

Aktien

A2QCEK

US01626L1052

ALGS

Andere Sprachen

Filter